CohBar的股东预计将持有约15%的CohBar普通股,合并前的Morphogenesis股东预计将持有约77%的CohBar普通股。
CohBar还与Morphogenesis现有投资者的关联公司签署了一...查看全文
蹊之美股生物医药2021-08-12 21:30
作者:林出
微信公众号:蹊之美股生物医药 / CaesarBiotech
Gainers:
CohBar (NASDAQ:CWBR)+25%Allied Healthcare Products (NASDAQ:AHPI)+18%Doximity (NYSE:DOCS)+33%Orphazyme (NASDAQ:ORPH) +16%Fulcrum Therapeutics (NASDAQ:FULC) +7%
Losers:
Biodesix...查看全文
蹊之美股生物医药2021-08-12 03:30
作者:王医生
微信公众号:蹊之美股生物医药 / CaesarBiotech
标的公司:CohBar, Inc. (NASDAQ:CWBR)
CohBar, Inc. (CWBR) 是一家临床阶段的生物技术公司,开发基于线粒体的疗法来治疗慢性疾病和延长健康寿命,该公司今天宣布了多中心、随机、双盲、安慰剂对照的 1a/1b 期临床试...查看全文
$CohBar(CWBR)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-22-027640 Act: 34 Size: 208 KB 网页链接
$CohBar(CWBR)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-22-027095 Act: 34 Size: 3 MB 网页链接
$CohBar(CWBR)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001213900-22-027083 Act: 34 Size: 289 KB 网页链接
$CohBar(CWBR)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001213900-22-025757 Act: 34 Size: 30 KB 网页链接
$CohBar(CWBR)$ DEF 14A Other definitive proxy statements Accession Number: 0001213900-22-021143 Act: 34 Size: 3 MB 网页链接
$CohBar(CWBR)$ PRE 14A Other preliminary proxy statements Accession Number: 0001213900-22-019410 Act: 34 Size: 786 KB 网页链接
$CohBar(CWBR)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001213900-22-015831 Act: 34 Size: 286 KB 网页链接
$CohBar(CWBR)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001213900-22-015833 Act: 34 Size: 6 MB 网页链接
$CohBar(CWBR)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001213900-22-015836 Act: 33 Size: 35 KB 网页链接
$CohBar(CWBR)$ 8-K Current report, item 5.02 Accession Number: 0001213900-22-011214 Act: 34 Size: 194 KB 网页链接